Author:
Awad Nadia I.,Brunetti Luigi,Juurlink David N.
Publisher
Springer Science and Business Media LLC
Subject
Health, Toxicology and Mutagenesis,Toxicology
Reference73 articles.
1. Pradaxa® [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2011 March. In.
2. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A (2010) Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103(6):1116–1127
3. Pradax® Canadian prescribing information [ http://www.boehringer-ingelheim.ca/en/Home/Human_Health/Our_Products/Product_Monographs/Pradax-pm.pdf ]
4. Hankey GJ, Eikelboom JW (2011) Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 123(13):1436–1450
5. Granger CB, Armaganijan LV (2012) Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation 125(1):159–164
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献